Filing Flows › Fate Therapeutics (FATE) › Q4 2024
Fate Therapeutics (FATE) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 5, 2025
Fate Therapeutics (FATE) reported revenue of $1.9M for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -39% from the quarter before.
Fate Therapeutics, Q4 2024: revenue $1.9M (+11% year over year), net loss $52.2M, operating cash flow −$27.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -39% | +11% |
| Operating profit | −$61.7M | — | — |
| Net earnings | −$52.2M | — | — |
| Operating cash flow | −$27.8M | — | — |
What changed
Revenue was $1.9M in Q4 2024, up 11% year over year and down 39% from the previous quarter.
Operating costs exceeded revenue by $61.7M, an operating margin of -3319.8%. Total costs grew 28% against revenue growth of 11%. The quarter ended with a net loss of $52.2M, wider than the previous quarter's $47.7M loss.
Operating cash flow was −$27.8M. Non-cash charges added back $4.8M of depreciation and amortization and $9.1M of share-based compensation. Working capital and other items added $10.4M. Capital expenditures of $98K exceeded it, leaving free cash flow of −$27.9M.
Questions
What was Fate Therapeutics' revenue in the fourth quarter 2024?
Fate Therapeutics (FATE) reported revenue of $1.9M for the fourth quarter 2024 (Q4 2024), +11% from a year earlier and -39% from the quarter before.
Source: Fate Therapeutics 10-K on SEC EDGAR.